Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

Good morning, Boston, and Happy National Handshake Day. Here are the five things you need to know in local business news to start your busy Thursday.

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...